Enzene Biosciences Limited

Enzene Biosciences is a global contract development and manufacturing organisation (CDMO) specialising in the development, manufacturing, and supply of biologics and biosimilars.

Founded in 2015, Enzene Biosciences has rapidly evolved into a prominent player in the biopharmaceutical industry. The company operates state-of-the-art research and development (R&D) and clinical-scale Good Manufacturing Practice (GMP) facilities in Pune, India, and the United States. Enzene's mission is to transform global healthcare by delivering trusted and affordable medicines that enhance the quality of life for patients worldwide.

A cornerstone of Enzene's innovative approach is EnzeneX™, a patented continuous bioprocess manufacturing platform. This technology enables continuous production of biologics, leading to higher yields and significantly reduced production costs. By leveraging EnzeneX™, the company addresses complex challenges in biologics production, making therapies more accessible to patients globally.

Key Products and Services

Discovery and Development: Enzene offers comprehensive services from target identification and validation to antibody discovery and engineering. The company also provides custom reagents and assay development solutions, facilitating a streamlined route to market for biologic therapies.

Manufacturing: Utilising both fed-batch processes and the proprietary EnzeneX™ platform, Enzene provides drug substance and drug product manufacturing services. These services are designed to meet current and future needs, ensuring efficiency and scalability in biologics production.

Analytical and CMC Services: The company offers a range of analytical services, including method development, product characterisation, dynamic process screening, bioassay capabilities, and stability studies, ensuring the highest quality standards in product development.

Biologic Modalities: Enzene's expertise encompasses a wide array of biologic modalities, such as monoclonal antibodies, therapeutic recombinant proteins, recombinant enzymes, conjugated therapeutic proteins, bispecific proteins, fusion proteins, synthetic peptides, plasmid DNA (pDNA), and phytopharmaceuticals.

Portfolio and Licensing: Enzene offers exclusive biosimilar licensing opportunities and Adeno-Associated Virus (AAV) kits for gene therapy applications. The company's biosimilar pipeline includes products in various stages of development, from pre-clinical to late stages, providing end-to-end biosimilar development and manufacturing services.

Enzene Biosciences is committed to revolutionising the biopharmaceutical landscape through continuous innovation and technological advancement. By providing integrated CDMO solutions and maintaining a robust pipeline of biosimilars, Enzene strives to bring life-changing medicines to patients swiftly and cost-effectively, thereby making a positive global impact on healthcare.